Frederic M. Vaz
Amsterdam, NH, Netherlands
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 229 publications
Correction: Microglial 5-LOX-activating protein antagonism alleviates leukotriene-driven neuroinflammation.
Journal: Acta neuropathologica
Published: September 04, 2026
DHDDS-related juvenile parkinsonism is caused by impaired lipid metabolism, glycosylation, and mitochondrial dysfunction, which can be rescued by NAD⁺ treatment.
Journal: medRxiv : the preprint server for health sciences
Published: June 12, 2026
Microglial 5-LOX-activating protein antagonism alleviates leukotriene-driven neuroinflammation.
Journal: Acta neuropathologica
Published: January 13, 2026
Microglial 5-LOX-activating protein antagonism alleviates leukotriene-driven neuroinflammation.
Journal: Acta neuropathologica
Published: January 13, 2026
Safety and Effectiveness of Pharmacy Compounded Chenodeoxycholic Acid Capsules for Patients With Cerebrotendinous Xanthomatosis.
Journal: Journal of inherited metabolic disease
Published: December 24, 2025
HEPES in Cell Culture Alters the Multi-Omics Profile Exhibited by Gaucher Disease Fibroblasts.
Journal: Journal of cellular biochemistry
Published: August 26, 2025
Direct Prediction of VLCADD Severity Using Newborn Screening Analyte Data.
Journal: Journal of inherited metabolic disease
Published: July 15, 2025
Alpha-methylacyl-CoA racemase (AMACR) deficiency: report on novel patient and literature review.
Journal: Journal of applied genetics
Published: July 07, 2025
Metachromatic Leukodystrophy: New Therapy Advancements and Emerging Research Directions.
Journal: Neurology
Published: June 27, 2025
Two new cases of KYNU deficiency: Further delineation of the phenotypic and biochemical spectrum and exploration of treatment options.
Journal: Molecular genetics and metabolism
Published: May 28, 2025
Last Updated: 09/26/2026